Princeton Global Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Princeton Global Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.36K	Buy	+25	New	+$1.32K	﹤0.01%	770
2022 Q4	–	Sell	-70	Closed	-$5K	–	556
2022 Q3	$5K	Hold	70	–	–	﹤0.01%	448
2022 Q2	$4K	Hold	70	–	–	﹤0.01%	482
2022 Q1	$4K	Sell	70 -240	-77%	-$15.1K	﹤0.01%	512
2021 Q4	$23K	Sell	310 -3,899	-93%	-$341K	0.01%	323
2021 Q3	$471K	Sell	4,209 -350	-8%	-$44K	0.14%	127
2021 Q2	$738K	Buy	4,559 +259	+6%	+$31.5K	0.22%	103
2021 Q1	$524K	Buy	+4,300	New	+$649K	0.17%	117

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Princeton Global Asset Management's CRSP Position: Q2 2026 in Review

Princeton Global Asset Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 25 shares worth $1.36K. The stake represents ﹤0.01% of the portfolio and ranks #770 among its holdings. This is a return to the name: Princeton Global Asset Management previously reported a position in CRSP as recently as Q3 2022.

Princeton Global Asset Management first reported a position in CRSP in Q1 2021 and has held it in 8 quarters since. The position peaked at $738K in Q2 2021. 54 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Princeton Global Asset Management held 25 shares of CRISPR Therapeutics worth $1.36K as of Q2 2026.
CRISPR Therapeutics was a new Princeton Global Asset Management position in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Princeton Global Asset Management's portfolio in Q2 2026, its #770 holding.
Princeton Global Asset Management first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 8 quarters since.
Princeton Global Asset Management's CRISPR Therapeutics position peaked at $738K in Q2 2021.
54 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.